Latest Healthcare News

EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.

PM Capital Global Opportunities Fund (ASX: PGF) is raising up to $195 million through a $175 million placement and a $20 million share purchase plan at $3.07 per share, matching its net tangible asset value and offering a fully franked 7.5 cent dividend for 2026.

LTR Pharma reports a 93% response rate in men seeking convenience and spontaneity with SPONTAN, alongside a 64% response in post-prostatectomy patients, highlighting potential for its rapid-onset intranasal ED treatment in challenging populations.

ReNerve Limited has gained marketing approval for its flagship NervAlign Nerve Cuff in India, marking a critical milestone in its global expansion and enabling commercial rollout in one of the world's largest nerve repair markets.

PM Capital Global Opportunities Fund Limited delivered a 41.5% jump in profit after tax to $238 million for FY26 and raised its fully franked dividend guidance to 16 cents for FY27, reflecting strong portfolio returns and robust earnings reserves.

Integral Diagnostics (ASX: IDX) posted strong preliminary FY26 results with revenue nearing $790 million and operating EBITDA up 30%, while announcing Jenny Martin as incoming CFO amid leadership transitions.

Austco Healthcare is acquiring Medical Communications Systems to deepen its direct sales footprint in South Australia, continuing a string of reseller takeovers that bolster its market presence and earnings.

Arena REIT faces a rent payment default from key tenant Edge Early Learning, representing 14% of rental income, prompting default notices and a delay in FY2026 financial results.

Talius has secured a substantial $850,000 purchase order from New Zealand’s Hato Hone St John, adding 8,000 devices and boosting its recurring revenue by $55,000 annually.

Flagship Investments Limited reported a sharp 24.1% portfolio decline for the year ended 30 June 2026, underperforming the ASX All Ordinaries Index by 21.7 percentage points. Despite this, the company declared a fully franked final dividend of 5.3 cents per share, supported by retained earnings.

Kingfish Limited posted a net loss of NZD 13.6 million for FY2026, underperforming the NZX50 benchmark, but showed early signs of recovery in FY2027. The company re-elected two directors and maintained its focus on quality growth stocks amid a cautious economic outlook.

Resmed delivered a strong FY2026 with 10% revenue growth to $5.7 billion, a 17% rise in non-GAAP EPS, and a 10% dividend hike. Strategic moves include selling MatrixCare and acquiring Noctrix Health.